Indivior Pharmaceuticals, Inc.
INDV
$36.76
-$1.07-2.83%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -11.45% | 14.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.45% | 14.01% | |||
| Cost of Revenue | -28.57% | 21.74% | |||
| Gross Profit | -8.28% | 12.69% | |||
| SG&A Expenses | -21.29% | 16.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -200.00% | |||
| Total Operating Expenses | -24.00% | 13.64% | |||
| Operating Income | 9.77% | 14.66% | |||
| Income Before Tax | 41.98% | 118.92% | |||
| Income Tax Expenses | 223.81% | -320.00% | |||
| Earnings from Continuing Operations | -12.75% | 142.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.75% | 142.86% | |||
| EBIT | 9.77% | 14.66% | |||
| EBITDA | 9.63% | 13.45% | |||
| EPS Basic | -12.48% | 144.05% | |||
| Normalized Basic EPS | 7.09% | 22.62% | |||
| EPS Diluted | -12.64% | 139.33% | |||
| Normalized Diluted EPS | 6.87% | 21.91% | |||
| Average Basic Shares Outstanding | -0.31% | -0.49% | |||
| Average Diluted Shares Outstanding | -0.09% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||